Details of the Drug Combination

General Information of Drug Combination (ID: DC9QRQI)

Drug Combination Name
ELLAGIC ACID Idarubicin
Indication
Disease Entry Status REF
Glioblastoma? Investigative [1]
Component Drugs ELLAGIC ACID   DMX8BS5 Idarubicin   DMM0XGL
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: T98G
Zero Interaction Potency (ZIP) Score: 22.12
Bliss Independence Score: 22.12
Loewe Additivity Score: 4.18
LHighest Single Agent (HSA) Score: 4.18

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of ELLAGIC ACID
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [2]
ELLAGIC ACID Interacts with 14 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Carbonic anhydrase VI (CA-VI) TTCFSPE CAH6_HUMAN Inhibitor [7]
Carbonic anhydrase I (CA-I) TTHQPL7 CAH1_HUMAN Inhibitor [7]
Carbonic anhydrase XII (CA-XII) TTSYM0R CAH12_HUMAN Inhibitor [7]
Carbonic anhydrase II (CA-II) TTANPDJ CAH2_HUMAN Inhibitor [7]
Carbonic anhydrase XIV (CA-XIV) TTEYTKG CAH14_HUMAN Inhibitor [7]
Mothers against decapentaplegic homolog 3 (SMAD3) TTHQZV7 SMAD3_HUMAN Inhibitor [8]
Carbonic anhydrase (CA) TTUNARX NOUNIPROTAC Inhibitor [7]
Heat shock protein 70 (HSP70) TTHYBIX HS71A_HUMAN; HS71B_HUMAN Inhibitor [8]
Casein kinase II alpha (CSNK2A1) TTER6YH CSK21_HUMAN Inhibitor [9]
Carbonic anhydrase IV (CA-IV) TTZHA0O CAH4_HUMAN Inhibitor [7]
Tyrosine-protein kinase SYK (SYK) TTOU65C KSYK_HUMAN Inhibitor [10]
Carbonic anhydrase IX (CA-IX) TT2LVK8 CAH9_HUMAN Inhibitor [7]
Glycogen synthase kinase-3 beta (GSK-3B) TTRSMW9 GSK3B_HUMAN Inhibitor [10]
Squalene monooxygenase (SQLE) TTE14XG ERG1_HUMAN Inhibitor [2]
------------------------------------------------------------------------------------
⏷ Show the Full List of 14 DTT(s)
ELLAGIC ACID Interacts with 92 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
DNA fragmentation factor subunit alpha (DFFA) OTFPFMT8 DFFA_HUMAN Decreases Expression [5]
Nucleolar protein 56 (NOP56) OTT67SRZ NOP56_HUMAN Decreases Expression [5]
Apoptotic protease-activating factor 1 (APAF1) OTJWIVY0 APAF_HUMAN Decreases Expression [5]
Glutathione S-transferase A4 (GSTA4) OTZ1USIA GSTA4_HUMAN Increases Expression [5]
Regulator of G-protein signaling 5 (RGS5) OTUY0Q2I RGS5_HUMAN Decreases Expression [5]
Transforming growth factor beta-1 proprotein (TGFB1) OTV5XHVH TGFB1_HUMAN Increases Expression [5]
Prostate-specific antigen (KLK3) OTFGSBFJ KLK3_HUMAN Decreases Expression [5]
Asparagine synthetase (ASNS) OT8R922G ASNS_HUMAN Increases Expression [5]
Extracellular superoxide dismutase (SOD3) OTIOZQAB SODE_HUMAN Decreases Expression [5]
Fibroblast growth factor receptor 1 (FGFR1) OT4GLCXW FGFR1_HUMAN Decreases Expression [5]
Prostatic acid phosphatase (ACP3) OTSIM0YG PPAP_HUMAN Increases Expression [5]
Insulin-like growth factor-binding protein 2 (IGFBP2) OTG1P60E IBP2_HUMAN Increases Expression [5]
Cyclic AMP-dependent transcription factor ATF-3 (ATF3) OTC1UOHP ATF3_HUMAN Increases Expression [5]
Pleiotrophin (PTN) OTYC7M2A PTN_HUMAN Decreases Expression [5]
Filamin-A (FLNA) OTYZ9JXM FLNA_HUMAN Decreases Expression [5]
Bone morphogenetic protein 6 (BMP6) OT9WN536 BMP6_HUMAN Decreases Expression [5]
Insulin-like growth factor-binding protein 4 (IGFBP4) OT2HZRBD IBP4_HUMAN Decreases Expression [5]
Calreticulin (CALR) OTYD2TR1 CALR_HUMAN Decreases Expression [5]
Transcription initiation factor IIE subunit beta (GTF2E2) OTDHCCCR T2EB_HUMAN Increases Expression [5]
Protein PML (PML) OT6SM2GD PML_HUMAN Decreases Expression [5]
Epidermal growth factor receptor substrate 15 (EPS15) OT7NPP8U EPS15_HUMAN Increases Expression [5]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Decreases Expression [5]
Achaete-scute homolog 1 (ASCL1) OTI4X44G ASCL1_HUMAN Increases Expression [5]
GTP-binding nuclear protein Ran (RAN) OT2TER5M RAN_HUMAN Decreases Expression [5]
Microtubule-associated protein 1A (MAP1A) OTHO8K43 MAP1A_HUMAN Decreases Expression [5]
Phosphatidylinositol-glycan-specific phospholipase D (GPLD1) OTUUQOVY PHLD_HUMAN Decreases Expression [5]
Transcription factor A, mitochondrial (TFAM) OTXXV5V7 TFAM_HUMAN Decreases Expression [5]
Nuclear factor NF-kappa-B p100 subunit (NFKB2) OTS231V7 NFKB2_HUMAN Decreases Expression [5]
Interferon regulatory factor 9 (IRF9) OTK4MYQJ IRF9_HUMAN Increases Expression [5]
Peroxisome proliferator-activated receptor delta (PPARD) OTI4WTOP PPARD_HUMAN Decreases Expression [5]
Transcription factor p65 (RELA) OTUJP9CN TF65_HUMAN Decreases Expression [5]
Proteolipid protein 2 (PLP2) OTEZ4LOV PLP2_HUMAN Increases Expression [5]
Early growth response protein 3 (EGR3) OTGPJIRA EGR3_HUMAN Decreases Expression [5]
Histone acetyltransferase p300 (EP300) OTL8QJDX EP300_HUMAN Increases Expression [5]
Ras GTPase-activating-like protein IQGAP2 (IQGAP2) OTX2UA7P IQGA2_HUMAN Increases Expression [5]
cGMP-dependent protein kinase 1 (PRKG1) OTPAS4LF KGP1_HUMAN Decreases Expression [5]
Septin-2 (SEPTIN2) OT3G33TM SEPT2_HUMAN Increases Expression [5]
Monocyte to macrophage differentiation factor (MMD) OTB5I4OC PAQRB_HUMAN Increases Expression [5]
TATA box-binding protein-associated factor RNA polymerase I subunit C (TAF1C) OTNV4CDH TAF1C_HUMAN Decreases Expression [5]
Neuronatin (NNAT) OTNRLO7G NNAT_HUMAN Increases Expression [5]
Hypoxia-inducible factor 1-alpha (HIF1A) OTADSC03 HIF1A_HUMAN Decreases Expression [5]
Transcription factor E4F1 (E4F1) OTL5ESAC E4F1_HUMAN Increases Expression [5]
General transcription factor IIH subunit 4 (GTF2H4) OTPD1DIU TF2H4_HUMAN Increases Expression [5]
Histone-lysine N-methyltransferase EZH1 (EZH1) OTFLUU94 EZH1_HUMAN Increases Expression [5]
Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 (INPP5D) OT7I3U0G SHIP1_HUMAN Increases Expression [5]
Receptor-type tyrosine-protein phosphatase N2 (PTPRN2) OTL6SH28 PTPR2_HUMAN Increases Expression [5]
Transcription factor IIIB 90 kDa subunit (BRF1) OTQC6DMG TF3B_HUMAN Decreases Expression [5]
Transcription factor 12 (TCF12) OTZVONNU HTF4_HUMAN Increases Expression [5]
Lipopolysaccharide-induced tumor necrosis factor-alpha factor (LITAF) OTT5JX1F LITAF_HUMAN Increases Expression [5]
Neuronal PAS domain-containing protein 2 (NPAS2) OTMRT2TS NPAS2_HUMAN Increases Expression [5]
Immediate early response gene 2 protein (IER2) OT5OY8BO IER2_HUMAN Increases Expression [5]
Autophagy protein 5 (ATG5) OT4T5SMS ATG5_HUMAN Increases Expression [5]
Death domain-associated protein 6 (DAXX) OTX6O7PL DAXX_HUMAN Decreases Expression [5]
Poly(ADP-ribose) glycohydrolase (PARG) OT10JTIO PARG_HUMAN Decreases Activity [11]
Stearoyl-CoA desaturase (SCD) OTB1073G SCD_HUMAN Decreases Expression [12]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Decreases Expression [12]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Decreases Expression [12]
Monocyte differentiation antigen CD14 (CD14) OT83GJ47 CD14_HUMAN Decreases Expression [12]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Decreases Secretion [12]
Phospholipase A2, membrane associated (PLA2G2A) OT1NY7BF PA2GA_HUMAN Decreases Expression [12]
Interleukin-1 receptor type 1 (IL1R1) OTTU8959 IL1R1_HUMAN Decreases Expression [12]
Signal transducer and activator of transcription 3 (STAT3) OTAAGKYZ STAT3_HUMAN Decreases Expression [12]
Heme oxygenase 1 (HMOX1) OTC1W6UX HMOX1_HUMAN Increases Expression [13]
NAD(P)H dehydrogenase 1 (NQO1) OTZGGIVK NQO1_HUMAN Increases Expression [13]
Telomerase reverse transcriptase (TERT) OT085VVA TERT_HUMAN Increases Expression [14]
Apoptosis-inducing factor 1, mitochondrial (AIFM1) OTKPWB7Q AIFM1_HUMAN Increases Expression [6]
Reversion-inducing cysteine-rich protein with Kazal motifs (RECK) OT9QIHEQ RECK_HUMAN Increases Expression [15]
Coagulation factor XII (F12) OTBFD2FU FA12_HUMAN Increases Activity [16]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Decreases Expression [17]
Albumin (ALB) OTVMM513 ALBU_HUMAN Affects Binding [18]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Expression [17]
Transcription factor Jun (JUN) OTCYBO6X JUN_HUMAN Decreases Expression [19]
Cyclin-dependent kinase 1 (CDK1) OTW1SC2N CDK1_HUMAN Decreases Expression [6]
72 kDa type IV collagenase (MMP2) OT5NIWA2 MMP2_HUMAN Decreases Expression [17]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Decreases Expression [17]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [17]
Glucose-6-phosphate 1-dehydrogenase (G6PD) OT300SMK G6PD_HUMAN Decreases Activity [20]
Matrix metalloproteinase-9 (MMP9) OTB2QDAV MMP9_HUMAN Decreases Expression [17]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Increases Phosphorylation [21]
Nitric oxide synthase, inducible (NOS2) OTKKIOJ1 NOS2_HUMAN Decreases Expression [17]
Peroxisome proliferator-activated receptor gamma (PPARG) OTHMARHO PPARG_HUMAN Increases Expression [19]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Increases Expression [6]
Biotin--protein ligase (HLCS) OTPDUX30 BPL1_HUMAN Decreases Activity [22]
6-phosphogluconate dehydrogenase, decarboxylating (PGD) OTVG296F 6PGD_HUMAN Decreases Activity [20]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [17]
Mitogen-activated protein kinase kinase kinase 1 (MAP3K1) OTS3FVTY M3K1_HUMAN Decreases Expression [19]
Endonuclease G, mitochondrial (ENDOG) OT5IM7B3 NUCG_HUMAN Increases Expression [6]
Nuclear receptor subfamily 1 group I member 3 (NR1I3) OTS3SGH7 NR1I3_HUMAN Increases Activity [23]
Mitogen-activated protein kinase 11 (MAPK11) OT0AS010 MK11_HUMAN Increases Expression [19]
Nuclear factor erythroid 2-related factor 2 (NFE2L2) OT0HENJ5 NF2L2_HUMAN Increases Expression [24]
DNA oxidative demethylase ALKBH2 (ALKBH2) OTSQW0BG ALKB2_HUMAN Decreases Activity [25]
Bcl2-associated agonist of cell death (BAD) OT63ERYM BAD_HUMAN Increases Expression [6]
------------------------------------------------------------------------------------
⏷ Show the Full List of 92 DOT(s)
Indication(s) of Idarubicin
Disease Entry ICD 11 Status REF
Acute myelogenous leukaemia 2A41 Approved [3]
Acute myeloid leukaemia 2A60 Approved [4]
Adult acute monocytic leukemia N.A. Approved [3]
Childhood acute megakaryoblastic leukemia N.A. Approved [3]
Leukemia N.A. Approved [3]
Idarubicin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
DNA topoisomerase II (TOP2) TT0IHXV TOP2A_HUMAN; TOP2B_HUMAN Modulator [27]
------------------------------------------------------------------------------------
Idarubicin Interacts with 3 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [28]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [29]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [29]
------------------------------------------------------------------------------------
Idarubicin Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [30]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [30]
------------------------------------------------------------------------------------
Idarubicin Interacts with 9 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Estrogen receptor (ESR1) OTKLU61J ESR1_HUMAN Decreases Activity [26]
Heme oxygenase 1 (HMOX1) OTC1W6UX HMOX1_HUMAN Increases Expression [31]
Androgen receptor (AR) OTUBKAZZ ANDR_HUMAN Increases Activity [26]
Natriuretic peptides B (NPPB) OTSN2IPY ANFB_HUMAN Increases Expression [32]
Peroxisome proliferator-activated receptor gamma (PPARG) OTHMARHO PPARG_HUMAN Decreases Activity [26]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [33]
Peroxisome proliferator-activated receptor delta (PPARD) OTI4WTOP PPARD_HUMAN Decreases Activity [26]
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Decreases Activity [34]
Bile acid receptor (NR1H4) OTWZLPTB NR1H4_HUMAN Decreases Activity [26]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 DOT(s)

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4.
3 Idarubicin FDA Label
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7083).
5 Interactive gene expression pattern in prostate cancer cells exposed to phenolic antioxidants. Life Sci. 2002 Mar 1;70(15):1821-39.
6 Ellagic acid induces apoptosis in TSGH8301 human bladder cancer cells through the endoplasmic reticulum stress- and mitochondria-dependent signaling pathways. Environ Toxicol. 2014 Nov;29(11):1262-74. doi: 10.1002/tox.21857. Epub 2013 Mar 30.
7 Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
8 In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
9 Structural insight into human CK2alpha in complex with the potent inhibitor ellagic acid. Bioorg Med Chem Lett. 2009 Jun 1;19(11):2920-3.
10 Identification of ellagic acid as potent inhibitor of protein kinase CK2: a successful example of a virtual screening application. J Med Chem. 2006 Apr 20;49(8):2363-6.
11 The effect of dietary polyphenols on the epigenetic regulation of gene expression in MCF7 breast cancer cells. Toxicol Lett. 2010 Feb 1;192(2):119-25.
12 Anti-inflammatory effects of dietary phenolic compounds in an in vitro model of inflamed human intestinal epithelium. Chem Biol Interact. 2010 Dec 5;188(3):659-67.
13 Antioxidant action of ellagic acid ameliorates paraquat-induced A549 cytotoxicity. Biol Pharm Bull. 2013;36(4):609-15.
14 Effect of ellagic acid on the expression of human telomerase reverse transcriptase (hTERT) alpha+beta+ transcript in estrogen receptor-positive MCF-7 breast cancer cells. Clin Biochem. 2009 Sep;42(13-14):1358-62. doi: 10.1016/j.clinbiochem.2009.05.017. Epub 2009 Jun 6.
15 Zinc-chelation contributes to the anti-angiogenic effect of ellagic acid on inhibiting MMP-2 activity, cell migration and tube formation. PLoS One. 2011 May 4;6(5):e18986. doi: 10.1371/journal.pone.0018986.
16 Activation of Hageman factor (factor XII) by sulfatides and other agents in the absence of plasma proteases. J Lab Clin Med. 1983 Jul;102(1):31-45.
17 The effects of ellagic acid and other pomegranate (Punica granatum L.) derivatives on human gastric cancer AGS cells. Hum Exp Toxicol. 2022 Jan-Dec;41:9603271211064534. doi: 10.1177/09603271211064534.
18 Ellagic acid mitigates SNO-PDI induced aggregation of Parkinsonian biomarkers. ACS Chem Neurosci. 2014 Dec 17;5(12):1209-20. doi: 10.1021/cn500214k. Epub 2014 Oct 8.
19 In vitro antioxidant and antiproliferative effects of ellagic acid and its colonic metabolite, urolithins, on human bladder cancer T24 cells. Food Chem Toxicol. 2013 Sep;59:428-37. doi: 10.1016/j.fct.2013.06.025. Epub 2013 Jun 26.
20 Investigation of the effects of some phenolic compounds on the activities of glucose-6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase from human erythrocytes. J Biochem Mol Toxicol. 2014 Nov;28(11):510-4. doi: 10.1002/jbt.21592. Epub 2014 Aug 6.
21 Rubus?coreanus Miquel extract causes apoptosis of doxorubicin-resistant NCI/ADR-RES ovarian cancer cells via JNK phosphorylation. Mol Med Rep. 2016 May;13(5):4065-72. doi: 10.3892/mmr.2016.4996. Epub 2016 Mar 17.
22 Resveratrol compounds inhibit human holocarboxylase synthetase and cause a lean phenotype in Drosophila melanogaster. J Nutr Biochem. 2015 Nov;26(11):1379-84. doi: 10.1016/j.jnutbio.2015.07.004. Epub 2015 Jul 26.
23 Polyphenols in alcoholic beverages activating constitutive androstane receptor CAR. Biosci Biotechnol Biochem. 2011;75(8):1635-7. doi: 10.1271/bbb.110444. Epub 2011 Aug 7.
24 Ellagic acid protects human keratinocyte (HaCaT) cells against UVA-induced oxidative stress and apoptosis through the upregulation of the HO-1 and Nrf-2 antioxidant genes. Food Chem Toxicol. 2012 May;50(5):1245-55. doi: 10.1016/j.fct.2012.02.020. Epub 2012 Feb 22.
25 Hydrolyzable Tannins Are Iron Chelators That Inhibit DNA Repair Enzyme ALKBH2. Chem Res Toxicol. 2019 Jun 17;32(6):1082-1086. doi: 10.1021/acs.chemrestox.8b00398. Epub 2019 May 28.
26 Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor. Sci Rep. 2014 Sep 26;4:6437. doi: 10.1038/srep06437.
27 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
28 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
29 Amonafide L-malate is not a substrate for multidrug resistance proteins in secondary acute myeloid leukemia. Leukemia. 2008 Nov;22(11):2110-5.
30 In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin. Hematology. 2004 Jun;9(3):217-21.
31 A Quantitative Approach to Screen for Nephrotoxic Compounds In Vitro. J Am Soc Nephrol. 2016 Apr;27(4):1015-28. doi: 10.1681/ASN.2015010060. Epub 2015 Aug 10.
32 The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia. Neoplasma. 2005;52(5):430-4.
33 The induction of apoptosis by daunorubicin and idarubicin in human trisomic and diabetic fibroblasts. Cell Mol Biol Lett. 2008;13(2):182-94. doi: 10.2478/s11658-007-0045-7. Epub 2008 Apr 10.
34 Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94. doi: 10.1093/toxsci/kft205. Epub 2013 Sep 19.